Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Roche suffers setback...

    Roche suffers setback as severe asthma drug fails in one study

    Written by savita thakur thakur Published On 2016-03-01T10:29:20+05:30  |  Updated On 1 March 2016 10:29 AM IST
    Roche suffers setback as severe asthma drug fails in one study
    Zurich: Roche suffered a setback in its ambitions to build its presence in the emerging market for biotech asthma drugs on Monday when it announced that one of two identical studies failed to help patients as expected.

    The Swiss drugmaker said while the first final-stage Phase III study of lebrikizumab in people with severe asthma met its primary endpoint and significantly reduced exacerbations, the second did not.

    "We were hopeful these identical studies would confirm the Phase II results because there is still a significant unmet need for people with severe asthma," Chief Medical Officer and Head of Global Product Development Sandra Horning said in a statement.

    "These data require further interpretation and analyses are ongoing to better understand the results and determine next steps."

    Lebrikizumab, an injectable antibody drug that works by blocking a protein called interleukin-13, is designed to compete in a market for severe asthma treatments that analysts expect to be reasonably crowded. As a result, there is little for error in proving the benefits of lebrikizumab.

    Xolair, which was jointly developed by Roche and Novartis , was until recently the only biotech medicine approved for severe asthma patients. But GlaxoSmithKline has now launched a promising new product called Nucala and several other companies are working on rival biotech asthma drugs.

    There was better news for Roche on another front late on Friday when U.S. regulators granted approval for its drug Gazyva for certain people with previously treated follicular lymphoma.
    asthmaasthma drugGazyvaGlaxoSmithKlinelebrikizumabNovartisNucalaRocheRoche drug trial
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok